United States Patent and Trademark Office

Greenlines Technology Awarded First-ever US Patent for Carbon Credit Generation in the Mobility Sector

Retrieved on: 
Tuesday, October 17, 2023
Sustainability, Environmental Issues, Green Technology, Environment, Carbon, Patent, Food, European, United States Patent and Trademark Office, Conversion, Organization, Transport, World Resources Institute, MCE, United States Environmental Protection Agency, City, Carbon footprint, United States patent law, Water, Renewable energy, Greenline (Pennsylvania)

The landmark patent titled, "Methods and Systems for Conversion of Physical Movements to Carbon Units”, bears the US Patent Number US 11,774,255 B2, signifying the world’s first-ever instance of a process to generate carbon credits being awarded a patent.

Key Points: 
  • The landmark patent titled, "Methods and Systems for Conversion of Physical Movements to Carbon Units”, bears the US Patent Number US 11,774,255 B2, signifying the world’s first-ever instance of a process to generate carbon credits being awarded a patent.
  • “Securing the world’s first carbon credit generation process patent is a pivotal moment for us at Greenlines.
  • Greenlines’ patent empowers mobility aggregators such as trip planning applications, private mobility providers, transit agencies, and more, to incentivize and promote sustainable transportation choices.
  • By merging innovation with sustainability, Greenlines is revolutionizing carbon markets while providing customers in the mobility sector the ability to quantify, recognize, and monetize greenhouse gas emission reductions.

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

Retrieved on: 
Wednesday, October 11, 2023
Patent, ElectroCore, ECOR, United States Patent and Trademark Office, NVN, Pharmaceutical industry

U.S. Patent No.

Key Points: 
  • U.S. Patent No.
  • 11,779,756 entitled “Systems and Methods for Vagal Nerve Stimulation” was issued on October 10, 2023, and is generally related to a preferable treatment paradigm for nVNS that involves applying a single dose of stimulation for about 90 seconds to about 150 seconds, 2-4 times during a 24-hour period.
  • “Our intellectual property portfolio continues to grow,” stated Dan Goldberger, Chief Executive Officer of electroCore.
  • “This new patent strengthens our position around the application of non-invasive vagus nerve stimulation, and how frequently nVNS may be used by a patient or customer looking for relief.”

VoIP-Pal Receives Another Favorable IPR Decision from the USPTO

Retrieved on: 
Thursday, October 5, 2023
Patent, United States Patent and Trademark Office, PTAB, Patent Trial and Appeal Board, T-Mobile, IPR, Attention, Verizon Communications, Mobile phone, Generic drug, Amazon

Since 2016 there have been a total of 36 IPR petitions filed against VoIP-Pal.

Key Points: 
  • Since 2016 there have been a total of 36 IPR petitions filed against VoIP-Pal.
  • As a result of this latest action all IPR petitions against the Company have now been terminated and brought to a favorable conclusion.
  • Emil Malak, CEO of VoIP-Pal, said, “We are extremely pleased with this recent decision by the USPTO.
  • Patience is a virtue.”
    List of all IPR challenges filed since 2016:

Sports Data Labs, Inc. Announces Issuance of New U.S. Patent which Expands Scope for Health Drone

Retrieved on: 
Tuesday, October 10, 2023
Data Management, Consumer Electronics, Technology, Research, Sports, Other Defense, Data Analytics, Aerospace, Manufacturing, Mobile, Wireless, General Sports, Defense, Satellite, Professional Services, Artificial Intelligence, Biotechnology, Other Technology, Software, Health, Hardware, Science, AI, Multimedia, Patent, Animal, United States Patent and Trademark Office, Sport, Human, 1836 U.S. Patent Office fire, Invention, Intelligence, UAV

Sports Data Labs, Inc. (SD Labs), an award-winning leader in AI-based technology solutions, announced today that the United States Patent and Trademark Office has issued the company U.S. Patent No.

Key Points: 
  • Sports Data Labs, Inc. (SD Labs), an award-winning leader in AI-based technology solutions, announced today that the United States Patent and Trademark Office has issued the company U.S. Patent No.
  • 11,778,987 which expands its coverage for its novel unmanned aerial vehicle (UAV)-based system related to collecting, analyzing, distributing, and monitoring biological sensor data from humans and other animals.
  • “We are thrilled with the continued expansion of our IP Portfolio,” said Vivek Khare, Co-Founder & Chief Technology Officer of SD Labs.
  • “This increased scope enables significantly broader reach for our novel inventions and allows us to explore broader applications in health monitoring with our partners.”

SpineThera Celebrates Milestone Achievement with 6th Patent Issued by the US Patent and Trademark Office

Retrieved on: 
Thursday, October 5, 2023
Research, Surgery, Hospitals, FDA, Clinical Trials, Biotechnology, Physical Therapy, Radiology, Health, Science, Patent, Criticism of patents, Physician, United States Patent and Trademark Office, Patient, Sciatica, Clinical trial, News, Quality of life, United States patent law, Pharmaceutical industry

11,771,707 provides additional protection for SX600 and complements previously issued U.S. Patent Nos.

Key Points: 
  • 11,771,707 provides additional protection for SX600 and complements previously issued U.S. Patent Nos.
  • The newly granted ‘707’ patent underscores SpineThera’s ongoing dedication to developing novel medical technologies that enhance spinal health and improve patients' quality of life.
  • The invention covered by this patent is a result of years of research and development by SpineThera’s team of skilled scientists, engineers, and medical professionals.
  • This 6th US Patent provides additional depth and breadth to our patent portfolio covering our micro-suspension technology.

TETROUS, INC. ANNOUNCES ISSUE OF AN ADDITIONAL U.S. PATENT RELATED TO ENFIX™ DEMINERALIZED BONE FIBER IMPLANTS FOR SPORTS MEDICINE SURGICAL PROCEDURES

Retrieved on: 
Thursday, October 5, 2023
Patent, United States Patent and Trademark Office, Doctor of Philosophy, DBF, 1836 U.S. Patent Office fire, Failure, Anterior cruciate ligament, ACL, 3D printing

EnFix RC™, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair.

Key Points: 
  • EnFix RC™, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair.
  • The newly issued patent, titled "Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair", further augments Tetrous' strong portfolio of intellectual property covering demineralized cortical bone fiber implants, bone healing, and enhancement of tendon to bone repair.
  • "We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and has granted this additional patent.
  • "Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the next-generation enthesis repair market".

Meati Foods™ Receives U.S. Patent for MushroomRoot™ (Neurospora crassa) Food Applications

Retrieved on: 
Wednesday, October 4, 2023
Organic Food, Retail, Environment, Sustainability, Supermarket, Food, Beverage, Sprouts, 1836 U.S. Patent Office fire, Whole Foods Market, Patent, Powder, Mycelium, Nutrient, Seafood, Research, PIPA, UC Davis Department of Viticulture and Enology, Cardiovascular disease, Mr. Meaty, Death, United States Patent and Trademark Office, LEAP, UC, PDCAAS, AI, Malnutrition, Neurospora crassa, Health, Dietary supplement, Meijer

In collaboration with PIPA, Meati™ also completed a swift, AI-driven study on MushroomRoot’s health benefits.

Key Points: 
  • In collaboration with PIPA, Meati™ also completed a swift, AI-driven study on MushroomRoot’s health benefits.
  • An additional set of rare compounds was identified that could yield even more pointed health benefits.
  • “The patent is a culmination of our years-long journey to have our foundational work with MushroomRoot and its wide-ranging food applications acknowledged and protected,” said Justin Whiteley, Meati co-founder and chief science officer.
  • 11,751,596 to Meati Foods on September 12, 2023, ensuring exclusivity over Meati’s N. crassa-based inventions until 2039.

Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity

Retrieved on: 
Wednesday, October 4, 2023
Patent, Sigyn, United States Patent and Trademark Office, Survival, Cancer, Toxicity, Patent Cooperation Treaty, PCT, REDUCE, Patient, SAN, United, Health, Therapy, Death, Pharmaceutical industry

Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States.

Key Points: 
  • Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States.
  • Achievement of this objective will likely improve treatment outcomes yet reduce treatment toxicity and long-term health consequences associated with chemotherapy administration.
  • Post infusion of chemotherapy, Sigyn Therapeutics designed ChemoPureTM to extract off-target drug agents from the bloodstream as a means to further reduce patient toxicity.
  • Sigyn Therapeutics previously disclosed that a related provisional patent application was filed with the United States Patent and Trademark Office (“USPTO”).

Neural Therapeutics Announces Board of Directors Appointments and IP Development Agreement with Validity Labs

Retrieved on: 
Tuesday, October 3, 2023
Aurora, CGS, Medical Affairs Bureau, CFA, Diabetes, Medicine, Doctor of Philosophy, BBA, Professor, Agreement, Science, Patent, University, Cardiovascular disease, Research, Certification, DEA, Geisel School of Medicine, Ernst, Ernst & Young, Drug Enforcement Administration, Metro, Grenadines, Clinical Laboratory, United States Patent and Trademark Office, Cancer, IP, CFO, Therapy, Pharmacy, Partnership, Drug development, Internet of things, General insurance, Canada Research Chair, Canada Research Chair in International Political Economy, Wilfrid Laurier University, Baylor College of Medicine, Pharmaceutical industry, Medical device, Nervous system, Molecular medicine

The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").

Key Points: 
  • The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").
  • Following these appointments, the board of directors of Neural is comprised of Ian Campbell, John Durfy, Colin McLelland, Dr. Kelly Narine and Dr. Jason Dyck.
  • Ian Campbell, CEO of Neural commented: "The expansion of our partnership with CGS and Validity Labs allows us to foster collaborative relationships with Validity Labs and leverage their extensive capabilities and expertise.
  • In connection with the Agreement entered between Neural and Validity Labs, Neural issued 500,000 common shares in the capital of Neural ("Neural Shares"), which was included in debt settlement issuance as outlined in Neural press release dated October 2, 2023.

A new creator brand emerges; Curios wins trademark protection for "Curios" and "Key to the Metaverse", acquires domain "cur.io"

Retrieved on: 
Thursday, September 28, 2023
Metaverse, Patent, Music, Platform as a service, Software as a service, Cryptocurrency, United States Patent and Trademark Office, Intelligence, G & S, Internet, Non-fungible token, Acquisition, FIRST, Machine learning, Love, Top-level domain, Growth, Environment, Software, 3D printing, Curio

AUSTIN, Texas, Sept. 28, 2023 /PRNewswire-PRWeb/ -- Curios, Inc. (Curios®), a leading innovator in the digital content creation and sharing space, is thrilled to announce that it has been awarded the coveted trademark rights for both "Curios" and "Key to the Metaverse" by the United States Patent and Trademark Office (USPTO). This achievement solidifies Curios' brand identity and strengthens its position in the competitive landscape of Web3 and online content platforms.

Key Points: 
  • This achievement solidifies Curios' brand identity and strengthens its position in the competitive landscape of Web3 and online content platforms.
  • In addition to securing the trademark rights, Curios is pleased to announce the acquisition of the domain name "cur.io."
  • - this domain name has been added to Curios' domain name portfolio which includes coveted TLDs such as "curios.com" and more.
  • The trademark serial number registered to Curios for "Curios" is 90772856, and provides the following description of Curios' goods and services:
    IC 036.